Fucidin® Cream in the Treatment of ImpetigoA phase IV study comparing clinical and bacteriological efficacy of Fucidin® cream with Fucidin® cream vehicle in the treatment of impetigo in paediatric patients

EO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S)0 个研究点目标入组 360 人开始时间: 2005年2月17日最近更新: 2013年7月15日

适应症

试验速览

暂无简介。

•Patients with a clinical diagnosis of impetigo, aged 2-11 years, of either sex, whose parent(s) has(ve) provided written consent, and with a severity score of minimum 1 for at least one of the following signs: Pustules/infected bullae, erythema and infiltration/induration.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Patients with other active inflammatory dermatitis at the area of impetigo, a temperature above 38.5 degrees C rectally (or equivalent), patients who have been administered topical or systemic Fucidin® or other antibacterial agents within the previous 4 weeks.

发起方

EO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S)